129 related articles for article (PubMed ID: 33883071)
1. Oncologic outcomes in resected ampullary cancer: Relevance of histologic subtype and adjuvant chemotherapy.
Affi Koprowski M; Sutton TL; Brinkerhoff BT; Grossberg A; Sheppard BC; Mayo SC
Am J Surg; 2021 Jun; 221(6):1128-1134. PubMed ID: 33883071
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
3. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
5. Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
Carter JT; Grenert JP; Rubenstein L; Stewart L; Way LW
J Am Coll Surg; 2008 Aug; 207(2):210-8. PubMed ID: 18656049
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study.
Robert PE; Leux C; Ouaissi M; Miguet M; Paye F; Merdrignac A; Delpero JR; Schwarz L; Carrere N; Muscari F; Gayet B; Dussart D; Hamy A; Regenet N
Pancreas; 2014 Jul; 43(5):692-7. PubMed ID: 24713843
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study.
Bolm L; Ohrner K; Nappo G; Rückert F; Zimmermann C; Rau BM; Petrova E; Honselmann KC; Lapshyn H; Bausch D; Weitz J; Sandini M; Keck T; Zerbi A; Distler M; Wellner UF
Pancreatology; 2020 Apr; 20(3):433-441. PubMed ID: 31987649
[TBL] [Abstract][Full Text] [Related]
8. Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater.
Miura JT; Jayakrishnan TT; Amini A; Johnston FM; Tsai S; Erickson B; Quebbeman EJ; Christians KK; Evans DB; Gamblin TC; Turaga KK
J Gastrointest Surg; 2014 Nov; 18(11):2003-8. PubMed ID: 25159502
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Narang AK; Miller RC; Hsu CC; Bhatia S; Pawlik TM; Laheru D; Hruban RH; Zhou J; Winter JM; Haddock MG; Donohue JH; Schulick RD; Wolfgang CL; Cameron JL; Herman JM
Radiat Oncol; 2011 Sep; 6():126. PubMed ID: 21951377
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
[TBL] [Abstract][Full Text] [Related]
13. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
Kang J; Lee W; Shin J; Park Y; Kwon JW; Jun E; Song KB; Lee JH; Hwang DW; Park SY; Kim SC
Langenbecks Arch Surg; 2022 May; 407(3):1091-1097. PubMed ID: 35013798
[TBL] [Abstract][Full Text] [Related]
14. Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.
Shaib WL; Sharma R; Brutcher E; Kim S; Maithel SK; Chen Z; Kooby DA; Kauh J; Landry J; El-Rayes BF
J Surg Oncol; 2014 May; 109(6):556-60. PubMed ID: 24338561
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.
Moekotte AL; Lof S; Van Roessel S; Fontana M; Dreyer S; Shablak A; Casciani F; Mavroeidis VK; Robinson S; Khalil K; Gradinariu G; Mowbray N; Al-Sarireh B; Fusai GK; Roberts K; White S; Soonawalla Z; Jamieson NB; Salvia R; Besselink MG; Abu Hilal M
Ann Surg; 2020 Dec; 272(6):1086-1093. PubMed ID: 30628913
[TBL] [Abstract][Full Text] [Related]
16. Is local resection adequate for T1 stage ampullary cancer?
Amini A; Miura JT; Jayakrishnan TT; Johnston FM; Tsai S; Christians KK; Gamblin TC; Turaga KK
HPB (Oxford); 2015 Jan; 17(1):66-71. PubMed ID: 25395092
[TBL] [Abstract][Full Text] [Related]
17. Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma.
Boyev A; Prakash LR; Chiang YJ; Newhook TE; Bruno ML; Arvide EM; Dewhurst WL; Kim MP; Ikoma N; Lee JE; Snyder RA; Tzeng CD; Katz MHG; Maxwell JE
Surg Oncol; 2023 Dec; 51():101994. PubMed ID: 37742542
[TBL] [Abstract][Full Text] [Related]
18. Invited Commentary: Adjuvant Chemotherapy Is Beneficial in Stage III Ampullary Adenocarcinoma.
Premji AM; Donahue TR
J Am Coll Surg; 2023 Sep; 237(3):512-514. PubMed ID: 37260119
[No Abstract] [Full Text] [Related]
19. [Prognostic factors in adenocarcinoma of the ampulla of Vater].
Fernández Aceñero MJ; Martínez Useros J; Díez-Valladares L; Ortega-Medina L; Pérez Aguirre E; de la Serna Esteban S; García Botella S; Díaz Del Arco C
Rev Esp Patol; 2018; 51(4):210-215. PubMed ID: 30269771
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte nuclear factor (HNF) 4α expression distinguishes ampullary cancer subtypes and prognosis after resection.
Ehehalt F; Rümmele P; Kersting S; Lang-Schwarz C; Rückert F; Hartmann A; Dietmaier W; Terracciano L; Aust DE; Jahnke B; Saeger HD; Pilarsky C; Grützmann R
Ann Surg; 2011 Aug; 254(2):302-10. PubMed ID: 21494118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
